Cancer Cachexia - Pipeline Review, H2 2013


#184796

116pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Cancer Cachexia Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. Cancer Cachexia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Cancer Cachexia.
  • A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cancer Cachexia Overview 7
Therapeutics Development 8
Pipeline Products for Cancer Cachexia - Overview 8
Pipeline Products for Cancer Cachexia - Comparative Analysis 9
Cancer Cachexia - Therapeutics under Development by Companies 10
Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes 13
Cancer Cachexia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Cancer Cachexia - Products under Development by Companies 17
Cancer Cachexia - Products under Investigation by Universities/Institutes 18
Cancer Cachexia - Companies Involved in Therapeutics Development 19
Amgen Inc. 19
Eli Lilly and Company 20
Novartis AG 21
Aphios Corporation 22
GTx, Inc. 23
AEterna Zentaris Inc. 24
Helsinn Healthcare S.A. 25
Alder Biopharmaceuticals Inc. 26
Vicus Therapeutics, LLC 27
Ohr Pharmaceutical Inc. 28
KAEL-GemVax Co., Ltd. 29
XBiotech USA, Inc. 30
Acacia Pharma Ltd. 31
PsiOxus Therapeutics, Ltd. 32
Signablok, Inc 33
Myomics, Inc. 34
Sprint Bioscience AB 35
Itis Pharmaceuticals Pty Ltd 36
Cancer Cachexia - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 42
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Assessment by Therapeutic Class 49
Drug Profiles 52
enobosarm - Drug Profile 52
anamorelin hydrochloride - Drug Profile 54
Xilonix - Drug Profile 56
macimorelin acetate - Drug Profile 58
clazakizumab - Drug Profile 60
anamorelin hydrochloride - Drug Profile 62
(megestrol + formoterol) - Drug Profile 64
(etodolac + propranolol) - Drug Profile 65
OHR/AVR-118 - Drug Profile 67
MT-102 - Drug Profile 69
LY-2495655 - Drug Profile 71
bimagrumab - Drug Profile 72
IP-1510 - Drug Profile 74
IP-1510 - Drug Profile 75
dronabinol - Drug Profile 76
tertomotide - Drug Profile 77
Ghrelin Receptor Agonists - Drug Profile 79
Drug Targeting Vps34 - Drug Profile 80
L-379 - Drug Profile 81
Activin Type IIB Receptor Antagonist - Drug Profile 82
DCB-CA2 - Drug Profile 83
Drug For Cancer Cachexia - Drug Profile 84
Drug Targeting Glutaminase - Drug Profile 85
Drugs For Cancer Cachexia - Drug Profile 86
Cancer Cachexia - Recent Pipeline Updates 87
Cancer Cachexia - Dormant Projects 102
Cancer Cachexia - Discontinued Products 103
Cancer Cachexia - Product Development Milestones 104
Featured News & Press Releases 104

Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 114
Disclaimer 114

Number of Products under Development for Cancer Cachexia, H2 2013 10
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Development by Companies, H2 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2013 15
Comparative Analysis by Late Stage Development, H2 2013 16
Comparative Analysis by Clinical Stage Development, H2 2013 17
Comparative Analysis by Early Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Cancer Cachexia - Pipeline by Amgen Inc., H2 2013 21
Cancer Cachexia - Pipeline by Eli Lilly and Company, H2 2013 22
Cancer Cachexia - Pipeline by Novartis AG, H2 2013 23
Cancer Cachexia - Pipeline by Aphios Corporation, H2 2013 24
Cancer Cachexia - Pipeline by GTx, Inc., H2 2013 25
Cancer Cachexia - Pipeline by AEterna Zentaris Inc., H2 2013 26
Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2013 27
Cancer Cachexia - Pipeline by Alder Biopharmaceuticals Inc., H2 2013 28
Cancer Cachexia - Pipeline by Vicus Therapeutics, LLC, H2 2013 29
Cancer Cachexia - Pipeline by Ohr Pharmaceutical Inc., H2 2013 30
Cancer Cachexia - Pipeline by KAEL-GemVax Co., Ltd., H2 2013 31
Cancer Cachexia - Pipeline by XBiotech USA, Inc., H2 2013 32
Cancer Cachexia - Pipeline by Acacia Pharma Ltd., H2 2013 33
Cancer Cachexia - Pipeline by PsiOxus Therapeutics, Ltd., H2 2013 34
Cancer Cachexia - Pipeline by Signablok, Inc, H2 2013 35
Cancer Cachexia - Pipeline by Myomics, Inc., H2 2013 36
Cancer Cachexia - Pipeline by Sprint Bioscience AB, H2 2013 37
Cancer Cachexia - Pipeline by Itis Pharmaceuticals Pty Ltd, H2 2013 38
Assessment by Monotherapy Products, H2 2013 39
Assessment by Combination Products, H2 2013 40
Number of Products by Stage and Target, H2 2013 43
Number of Products by Stage and Mechanism of Action, H2 2013 46
Number of Products by Stage and Route of Administration, H2 2013 48
Number of Products by Stage and Molecule Type, H2 2013 50
Number of Products by Stage and Therapeutic Class, H2 2013 53
Cancer Cachexia Therapeutics - Recent Pipeline Updates, H2 2013 89
Cancer Cachexia - Dormant Projects, H2 2013 104
Cancer Cachexia - Discontinued Products, H2 2013 105
Number of Products under Development for Cancer Cachexia, H2 2013 10
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 12
Comparative Analysis by Early Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 39
Number of Products by Top 10 Target, H2 2013 41
Number of Products by Stage and Top 10 Target, H2 2013 42
Number of Products by Top 10 Mechanism of Action, H2 2013 44
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 45
Number of Products by Top 10 Route of Administration, H2 2013 47
Number of Products by Stage and Top 10 Route of Administration, H2 2013 48
Number of Products by Top 10 Molecule Type, H2 2013 49
Number of Products by Stage and Top 10 Molecule Type, H2 2013 50
Number of Products by Top 10 Therapeutic Class, H2 2013 51
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 52